200,000+ products from a single source!

sales@angenechem.com

Home > Pyridines > 100299-08-9

100299-08-9

100299-08-9 | 4H-Pyrido[1,2-a]pyrimidin-4-one, 9-methyl-3-(2H-tetrazol-5-yl)-, potassium salt (1:1)

CAS No: 100299-08-9 Catalog No: AG0001HB MDL No:MFCD22575284

Product Description

Catalog Number:
AG0001HB
Chemical Name:
4H-Pyrido[1,2-a]pyrimidin-4-one, 9-methyl-3-(2H-tetrazol-5-yl)-, potassium salt (1:1)
CAS Number:
100299-08-9
Molecular Formula:
C10H8KN6O
Molecular Weight:
267.3084
MDL Number:
MFCD22575284
IUPAC Name:
potassium;9-methyl-3-(1,2,3-triaza-4-azanidacyclopenta-2,5-dien-5-yl)pyrido[1,2-a]pyrimidin-4-one
InChI:
InChI=1S/C10H7N6O.K/c1-6-3-2-4-16-9(6)11-5-7(10(16)17)8-12-14-15-13-8;/h2-5H,1H3;/q-1;+1
InChI Key:
NMMVKSMGBDRONO-UHFFFAOYSA-N
SMILES:
Cc1cccn2c1ncc(c2=O)c1n[nH]nn1.[K]
UNII:
497A17OUUE

Properties

Complexity:
495  
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
2  
Defined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
0
Exact Mass:
266.032g/mol
Formal Charge:
0
Heavy Atom Count:
18  
Hydrogen Bond Acceptor Count:
6  
Hydrogen Bond Donor Count:
0
Isotope Atom Count:
0
Molecular Weight:
266.305g/mol
Monoisotopic Mass:
266.032g/mol
Rotatable Bond Count:
1  
Topological Polar Surface Area:
72.3A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0

Literature

Title Journal
Pemirolast reduces cisplatin-induced kaolin intake in rats. European journal of pharmacology 20110701
[Toxicity of topical ocular anti-allergic agents on human corneal epithelial cells in vitro]. [Zhonghua yan ke za zhi] Chinese journal of ophthalmology 20100101
Suppressive activity of pemirolast potassium, an antiallergic drug, on glomerulonephritis. Studies in glomerulonephritis model rats and in patients with chronic glomerulonephritis concurrently affected by allergic rhinitis. Arzneimittel-Forschung 20080101
The effect of a combined therapy with a histamine H1 antagonist and a chemical mediator release inhibitor on allergic conjunctivitis. Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde 20080101
A late cutaneous response in actively sensitized rats: a new method for evaluating the efficacy of antiallergic drugs. Journal of pharmacological sciences 20060801
Prophylactic effect of pemirolast, an antiallergic agent, against hypersensitivity reactions to paclitaxel in patients with ovarian cancer. International journal of cancer 20060515
Tetrazole compounds: the effect of structure and pH on Caco-2 cell permeability. Journal of pharmaceutical sciences 20060401
Peripheral interstitial keratitis: a novel manifestation of ocular mastocytosis. Cornea 20060401
Comparison of antigen-induced leukotriene and histamine release from nasal scrapings in allergic rhinitis. Rhinology 20050901
Increasing effect by simultaneous use of levocabastine and pemirolast on experimental allergic conjunctivitis in rats. Biological & pharmaceutical bulletin 20050301
Pemirolast potently attenuates paclitaxel hypersensitivity reactions through inhibition of the release of sensory neuropeptides in rats. Neuropharmacology 20040501
A comparative trial of the safety and efficacy of 0.1 percent pemirolast potassium ophthalmic solution dosed twice or four times a day in patients with seasonal allergic conjunctivitis. Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics 20040401
Comparison of 0.1% bromfenac sodium and 0.1% pemirolast potassium for the treatment of allergic conjunctivitis. Japanese journal of ophthalmology 20040101
Preventive effect of an antiallergic drug, pemirolast potassium, on restenosis after stent placement: quantitative coronary angiography and intravascular ultrasound studies. Journal of cardiology 20030701
A combined analysis of two studies assessing the ocular comfort of antiallergy ophthalmic agents. Clinical therapeutics 20030401
Two mast cell stabilizers, pemirolast potassium 0.1% and nedocromil sodium 2%, in the treatment of seasonal allergic conjunctivitis: a comparative study. Advances in therapy 20030101
Pemirolast potassium 0.1% ophthalmic solution is an effective treatment for allergic conjunctivitis: a pooled analysis of two prospective, randomized, double-masked, placebo-controlled, phase III studies. Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics 20021001
Comparative effects of topical ocular anti-allergy drugs on human conjunctival mast cells. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 19971201
A pilot study of pemirolast in patients with seasonal allergic rhinitis. Annals of allergy 19910201

Related Products

© 2019 Angene International Limited. All rights Reserved.